![]() ![]() ![]() ![]() |
FDA
Home Page | CDRH Home Page | Search
| CDRH
A-Z Index | Contact CDRH
|
![]() |
![]() |
![]() ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
This is a brief overview of information related to FDA's approval to market this product. See the links below to the Summary of Safety and Effectiveness and product labeling for more complete information on this product, its indications for use, and the basis for FDA's approval.
Product Name: ExAblate® 2000 System
Applicant: InSightec
Address:
InSightec, Ltd.
7 Etgar St. Einstein Bldg.
New Industrial Zone
Tirat-Carmel 39120, Israel
US Representative
InSightec, Inc
2777 Stemmons Freeway, Suite 940
Dallas, Tx 75207-2273
Approval Date: October 22, 2004
Approval Letter: http://www.fda.gov/cdrh/pdf4/P040003a.pdf
What is it? ExAblate® 2000 is a new medical device that uses magnetic resonance image guided focused ultrasound to target and destroy uterine fibroids, non-cancerous masses located in the uterus. The device is intended to treat women who have completed child bearing or do not intend to become pregnant. ExAblate® 2000 is non-invasive surgery. It spares the uterus and is an alternative to myomectomy, hysterectomy, watchful waiting, hormone therapy, or uterine fibroid embolization. Treatment typically lasts about three hours.
How does it work? ExAblate® 2000 combines two systems:
(1) a focused ultrasound beam that heats and destroys the uterine fibroid tissue
using high-frequency, high-energy sound waves; and
(2) a magnetic
resonance imaging (MRI) and thermal mapping system to visualize patient
anatomy, map the volume of fibroid tissue to be treated, and monitor the temperature
of the uterine tissue after heating.
This is the first time these two systems have been combined and the first time MRI has been used to monitor tissue temperature.
When is it used? The ExAblate® 2000 is intended for use in women who:
What will it accomplish? ExAblate® 2000 is a non-invasive surgical treatment that spares the uterus. It is used to treat patients with symptomatic fibroids who desire a decrease in symptoms caused by uterine fibroids.
When should it not be used? The ExAblate® 2000 treatment is contraindicated for use in women who have:
Additional information: Summary of Safety and Effectiveness and labeling will be available at: http://www.fda.gov/cdrh/pdf4/p040003.html
Other:
Updated November 3, 2004
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH